Wachovia downgrades ResMed (NYSE: RMD) from Outperform to Market Perform with a $51-$55 valuation range.

The firm gave several ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE